Kilpest India gets USFDA’s grant for multiplex real-time PCR test

19 Jun 2020 Evaluate

US Food and Drug Administration (USFDA) has granted emergency use authorization (EUA) to Kilpest India with its subsidiary -- 3B Blackbio Biotech India for its multiplex real-time PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2, the virus that causes COVID-19.

With this, 3B Blackbio Biotech India becomes first ever Indian molecular diagnostics company to receive US FDA-(EUA). Especially at times when more and more reliable testing is the need of the hour for India as well as other countries, TRUPCR will be reliable options for labs across the globe to perform the molecular testing for Covid-19 suspected individuals.

Kilpest India is one of India's leading agri-based companies. The Company manufactures, imports, exports, buys, and sells biological compounds derived from plants, animals, micro organisms.

3B Blackbio Dx Share Price

1414.00 34.50 (2.50%)
15-Dec-2025 13:10 View Price Chart
Peers
Company Name CMP
Poly Medicure 1871.15
Laxmi Denta 267.10
Nureca Ltd. 283.15
Hemant Surgical Inds 300.00
3B Blackbio Dx 1414.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×